Abstract
Purpose
To investigate serum 25-hydroxyvitamin D 25(OH)D status and assess the predictability of outcome in patients with Graves’ disease (GD) who received a patient-specific calculated dose of radioiodine therapy (RIT).
Methods
128 patients with GD who received RIT from July 2010 to September 2010 were included. Pre-therapy serum levels of 25(OH)D, calcium, phosphorus, parathyroid hormone, free triiodothyronine, free thyroxine, thyroid stimulating hormone and creatinine were measured. 60 age- and BMI-matched healthy subjects were chosen as the normal control group.
Results
Post-therapy follow-up results revealed that therapy failed in 25.00 % of the patients. Serum 25(OH)D levels were found to be significantly lower in patients who failed in therapy. The prevalence of vitamin D deficiency in GD patients was significantly higher compared with control subjects (56.25 vs. 10.00 %, P < 0.001), and therapy failed in 27 (37.50 %) of these patients whose serum 25(OH)D levels < 20 ng/ml. Out of the 56 patients (43.75 %) in whom serum 25(OH)D levels ≥20 ng/ml, therapy was unsuccessful in only 5 (8.93 %). Cox regression analysis suggested that serum 25(OH)D levels <20 ng/ml might be an independent risk factor for predicting failure of RIT in GD patients (relative risk = 8.83, 95 % confidence interval = 3.34–23.38, P < 0.001).
Conclusions
Serum 25(OH)D levels were lower in patients who failed than in those who succeeded in RIT of GD. Therefore, serum 25(OH)D < 20 ng/ml might be an independent risk factor for predicting failure of RIT in GD patients.
Similar content being viewed by others
References
Cooper GS, Stroehla BC (2003) The epidemiology of autoimmune diseases. Autoimmun Rev 2:119–125
McLeod DS, Cooper DS (2012) The incidence and prevalence of thyroid autoimmunity. Endocrine 42:252–265
Wartofsky L, Glinoer D, Solomon B et al (1991) Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1:129–135
Alexander EK, Larsen PR (2002) High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 87:1073–1077
Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA (2001) Radioiodine treatment of hyperthyroidism—prognostic factors for outcome. J Clin Endocrinol Metab 86:3611–3617
Walter MA, Christ-Crain M, Eckard B et al (2004) Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest 34:365–370
Bogazzi F, Giovannetti C, Fessehatsion R et al (2010) Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 95:201–208
Zantut-Wittmann DE, Ramos CD, Santos AO et al (2005) High pre-therapy [99mTc] pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I] iodide therapy in Graves’ disease. Nucl Med Commun 26:957–963
Song HR, Park CH (2013) Low serum vitamin D level is associated with high risk of metabolic syndrome in post-menopausal women. J Endocrinol Invest 36:791–796
Mete T, Yalcin Y, Berker D et al (2013) Obstructive sleep apnea syndrome and its association with vitamin D deficiency. J Endocrinol Invest 36:681–685
Tamer G, Arik S, Tamer I, Coksert D (2011) Relative vitamin D insufficiency in Hashimoto’s thyroiditis. Thyroid 21:891–896
Yasuda T, Okamoto Y, Hamada N et al (2012) Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves’ disease. Endocrine 42:739–741
Yasuda T, Okamoto Y, Hamada N et al (2013) Serum vitamin D levels are decreased in patients without remission of Graves’ disease. Endocrine 43:230–232
Isgoren S, Daglioz Gorur G, Demir H, Berk F (2012) Radioiodine therapy in Graves’ disease: is it possible to predict outcome before therapy? Nucl Med Commun 33:859–863
de Jong JA, Verkooijen HM, Valk GD, Zelissen PM, de Keizer B (2013) High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med 38:401–406
Ralston SH, Binkley N, Boonen S et al (2011) Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcif Tissue Int 88:485–494
Kalinyak JE, McDougall IR (2003) How should the dose of iodine-131 be determined in the treatment of Graves’ hyperthyroidism? J Clin Endocrinol Metab 88:975–977
Nordyke RA, Gilbert FI Jr (1991) Optimal iodine-131 dose for eliminating hyperthyroidism in Graves’ disease. J Nucl Med 32:411–416
Kok SW, Smit JW, de Craen AJ et al (2000) Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: an equivalence study. Nucl Med Commun 21:1071–1078
Chiovato L, Fiore E, Vitti P et al (1998) Outcome of thyroid function in Graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 83:40–46
Bech K, Nistrup Madsen S (1980) Influence of treatment with radioiodine and propylthiouracil on thyroid stimulating immunoglobulins in Graves’ disease. Clin Endocrinol 13:417–424
Andrade VA, Gross JL, Maia AL (2004) Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves’ patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study. Eur J Endocrinol 151:467–474
Chiappori A, Villalta D, Bossert I et al (2010) Thyrotropin receptor autoantibody measurement following radiometabolic treatment of hyperthyroidism: comparison between different methods. J Endocrinol Invest 33:197–201
Laurberg P, Wallin G, Tallstedt L et al (2008) TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69–75
Blomgren H, Wasserman J, Petrini B, von Stedingk LV (1991) Blood lymphocyte population following 131I treatment for hyperthyroidism. Acta Endocrinol 124:152–158
Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15:2579–2585
Bischoff-Ferrari HA (2014) Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 810:500–525
van Etten E, Mathieu C (2005) Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101
Cantorna MT, Zhu Y, Froicu M, Wittke A (2004) Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 80:1717s–1720s
Coffman RL, Varkila K, Scott P, Chatelain R (1991) Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol Rev 123:189–207
Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C (2010) Vitamin D: modulator of the immune system. Curr Opin Pharmacol 10:482–496
Rotondi M, Chiovato L (2013) Vitamin D deficiency in patients with Graves’s disease: probably something more than a casual association. Endocrine 43:3–5
Misharin A, Hewison M, Chen CR et al (2009) Vitamin D deficiency modulates Graves’ hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization. Endocrinology 150:1051–1060
Romagnoli E, Carnevale V, Biondi P, Minisola S (2014) Vitamin D supplementation: when and how? J Endocrinol Invest 37:603–607
Acknowledgments
The authors thank Dr. Amal Kumar Ghimeray and Prof. Weicheng Hu for assisting in preparation of this manuscript.
Conflict of interest
The authors have no conflict of interests.
Ethical approval
Ethical approval was given by the medical ethics committee of Huai’an First People’s Hospital, Nanjing Medical University, with the following reference number: IRB-PJ2010-002-01. All procedures performed in studies involving human participants were in accordance with the ethical standards of the research committee of University.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Author information
Authors and Affiliations
Corresponding author
Additional information
X. Li and G. Wang contributed equally to this work.
Rights and permissions
About this article
Cite this article
Li, X., Wang, G., Lu, Z. et al. Serum 25-hydroxyvitamin D predict prognosis in radioiodine therapy of Graves’ disease. J Endocrinol Invest 38, 753–759 (2015). https://doi.org/10.1007/s40618-015-0252-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-015-0252-4